Pfizer Inc (PFE) 32.43 $PFE
The Zacks Analyst Blog Highlights: Skyworks Solutions, United Online, National Commerce, Hospira and Pfizer
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 8:30AM CDT
The Zacks Analyst Blog Highlights: Skyworks Solutions, United Online, National Commerce, Hospira and Pfizer
SWKS: 86.15 (+5.59), PFE: 32.43 (+1.09), NCOM: 23.33 (+0.32), UNTD: 11.07 (+0.12), HSP: 89.84 (+0.01)
Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE(R) (palbociclib), for Patients with Hormone Receptor-Positive Early Breast Cancer
Business Wire - Wed Aug 26, 6:30AM CDT
The Alliance Foundation Trials, LLC (AFT), the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and Pfizer Inc. today announced the launch of the Palbociclib Collaborative Adjuvant Study, or PALLAS. This global Phase 3 clinical trial for patients with early-stage breast cancer is being conducted in conjunction with Breast International Group (BIG), German Breast Group (GBG), National Surgical Adjuvant Breast and Bowel Project (NSABP) and PrECOG, LLC (PrECOG). The PALLAS trial will evaluate whether the addition of IBRANCE(R) (palbociclib), developed by Pfizer, to standard therapy will improve disease-free survival and prevent the disease from recurring. Patients treated in this study will have cancers that are hormone receptor-positive (HR+), meaning their growth is fueled by the hormone estrogen, but are negative for human epidermal growth factor receptor 2 (HER2-), a different tumor-associated protein. About 60 to 65 percent of breast cancers in the United States fall into this category.i
PFE: 32.43 (+1.09)
Alvogen to Acquire Product Portfolio from Pfizer for the U.S. Market
Business Wire - Wed Aug 26, 5:12AM CDT
Alvogen has entered into a definitive agreement with Pfizer Inc. (NYSE: PFE), under which it will acquire a portfolio of four pharmaceutical products, in the U.S.
PFE: 32.43 (+1.09)
Best Buy and DSW are big market movers
AP - Tue Aug 25, 3:37PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
MDT: 72.24 (+2.36), EXC: 31.44 (+1.04), PFE: 32.43 (+1.09), GAS: 60.79 (-0.05), SAFM: 68.19 (+0.35), BBY: 35.25 (+2.30), BAC: 16.06 (+0.80), EPZM: 17.52 (+0.48), BA: 129.34 (+3.85), SO: 43.61 (+1.11), ECA.TO: 8.34 (+0.34), HSP: 89.84 (+0.01), CIE: 7.92 (-0.02), EXCU: 46.82 (+1.31), DSW: 28.67 (+1.32), ECA: 6.26 (+0.27), POM: 23.40 (+0.89), WB: 11.00 (+0.34), CVX: 73.09 (+3.07)
When Looking for Market Help, Rigor Is Essential
at The Street - Tue Aug 25, 11:01AM CDT
USA Today's '9 Stocks' story doesn't consider data essential to its narrative.
PLL: 126.57 (+0.30), SIAL: 139.01 (-0.05), PFE: 32.43 (+1.09), DHR: 86.67 (+3.44), SO: 43.61 (+1.11), HSP: 89.84 (+0.01)
These 4 Resilient Stocks Survived Monday's Selloff
Swarup Gupta - Zacks Investment Research - Tue Aug 25, 9:15AM CDT
Stocks which have survived the strongest selloff in recent times make for good additions to your portfolio.
SWKS: 86.15 (+5.59), NCOM: 23.33 (+0.32), PFE: 32.43 (+1.09), UNTD: 11.07 (+0.12), HSP: 89.84 (+0.01)
Company News for August 25, 2015
Zacks Equity Research - Zacks Investment Research - Tue Aug 25, 9:10AM CDT
Companies in the News are: GAS,SO,HSP,PFE,TOUR,QFOR
PFE: 32.43 (+1.09), GAS: 60.79 (-0.05), SO: 43.61 (+1.11), TOUR: 11.40 (-1.55), HSP: 89.84 (+0.01)
Pfizer's Stephen Baker Joins Innovive Inc
Business Wire - Tue Aug 25, 7:00AM CDT
Innovive Inc, the leader in disposable IVC rodent caging, today announced that Stephen Baker has joined the company as Vice President of Business Development.
PFE: 32.43 (+1.09)
Still Not Cheap? Not So Fast
at The Street - Tue Aug 25, 6:52AM CDT
This cautionary story misses big details about the stocks it's warning about.
PLL: 126.57 (+0.30), SIAL: 139.01 (-0.05), PFE: 32.43 (+1.09), DHR: 86.67 (+3.44), SO: 43.61 (+1.11), HSP: 89.84 (+0.01)
Pfizer awarded final regulatory approvals for pending acquisition of Hospira
M2 - Tue Aug 25, 4:06AM CDT
Pfizer (NYSE
FE) declared on Monday that the US Federal Trade Commission has terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to its pending acquisition of Hospira (NYSE:HSP).
PFE: 32.43 (+1.09), HSP: 89.84 (+0.01)
Pfizer says Hospira purchase will close in early September
AP - Mon Aug 24, 6:39PM CDT
NEW YORK (AP) — Drugmaker Pfizer says it's received the final regulatory approvals for its $15.23 billion purchase of the injectable drug and infusion device maker Hospira, and says the deal will close in early September.
PFE: 32.43 (+1.09), HSP: 89.84 (+0.01)
After Yesterday's Decline of 4.20%, Pfizer Offers Investors Better Value
Comtex SmarTrend(R) - Mon Aug 24, 4:53PM CDT
Pfizer (NYSEFE) traded in a range yesterday that spanned from a low of $28.47 to a high of $33.25. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $33.54 on volume of 51.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PFE: 32.43 (+1.09)
Pfizer Set to Possibly Rebound After Yesterday's Selloff of 4.20%
Comtex SmarTrend(R) - Mon Aug 24, 4:53PM CDT
Pfizer (NYSEFE) traded in a range yesterday that spanned from a low of $28.47 to a high of $33.25. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $33.54 on volume of 51.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PFE: 32.43 (+1.09)
Flash Crash-Like Selloff Met by Buyers; Cook’s Letter to Cramer Was ‘Significant’
at The Street - Mon Aug 24, 2:10PM CDT
The CNBC ‘Fast Money’ traders break down Monday’s violent selloff and subsequent rally. Apple CEO Tim Cook’s letter to Jim Cramer gave investors some clarity on China.
SBUX: 53.96 (+2.87), HD: 115.93 (+4.96), GILD: 106.96 (+4.40), PFE: 32.43 (+1.09), VZ: 45.16 (+1.66), AAPL: 109.69 (+5.95), CELG: 119.23 (+6.53)
Best in Breed: Where to Look If You Simply Must Buy Stocks Today
at The Street - Mon Aug 24, 12:00PM CDT
Limit your purchases to high-yielding industry standouts.
JNJ: 95.11 (+4.38), JPM: 62.91 (+3.00), IBM: 146.70 (+5.74), PFE: 32.43 (+1.09), KHC: 73.91 (+3.70), WMT: 64.83 (+1.73), XOM: 72.50 (+3.79), WFC: 52.30 (+2.28), BRK.B: 132.61 (+4.87), BRK.A: 200,499.92 (+6,300.00), AAPL: 109.69 (+5.95)
Pfizer (PFE) Crosses Pivot Point Support at $33.20
Comtex SmarTrend(R) - Mon Aug 24, 11:51AM CDT
Shares of Pfizer (NYSEFE) have bearishly opened below the pivot of $33.88 today and have reached the first support level of $33.20. Analysts will be watching for a cross of the next downside pivot targets of $32.86 and $31.84.
PFE: 32.43 (+1.09)
Pfizer (PFE) Stock Lower, Receives Regulatory Approval for Hospira Purchase
at The Street - Mon Aug 24, 10:28AM CDT
Pfizer (PFE) shares are down despite the company receiving regulatory approval for its $15.23 billion purchase of smaller rival Hospira (HSP).
PFE: 32.43 (+1.09)
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015
Business Wire - Mon Aug 24, 7:15AM CDT
--Results from the AEGEAN (Assessment of an Educational and Guidance Programme for Eliquis Adherence in Nonvalvular Atrial Fibrillation) study will also be presented as a late-breaking trial
PFE: 32.43 (+1.09), BMY: 60.03 (+2.15)
Halozyme Enzyme Could Boost Power Of Cancer Drugs
at Investor's Business Daily - Mon Aug 24, 7:02AM CDT
Halozyme Therapeutics has been one of 2015's hotter biotech stocks, but it's not exactly because of developing a drug. Halozyme's (HALO) one marketed product, Hylenex, aids in the delivery of injectable drugs. Halozyme has also licensed Enhanze for...
JNJ: 95.11 (+4.38), HALO: 17.46 (+0.58), PFE: 32.43 (+1.09), AMGN: 153.98 (+8.79), ABBV: 63.14 (+2.43), BXLT: 35.45 (+0.72), CELG: 119.23 (+6.53)
Pfizer Receives Clearance from U.S. Federal Trade Commission for Hospira Acquisition
Business Wire - Mon Aug 24, 7:00AM CDT
--Brazil's Superintendency-General of the Council for Economic Defense (CADE) has published its unconditional clearance decision
PFE: 32.43 (+1.09), HSP: 89.84 (+0.01)
The Zacks Analyst Blog Highlights: Skyworks Solutions, United Online, National Commerce, Hospira and Pfizer
Zacks Equity Research - Zacks Investment Research - Wed Aug 26, 8:30AM CDT
The Zacks Analyst Blog Highlights: Skyworks Solutions, United Online, National Commerce, Hospira and Pfizer
SWKS: 86.15 (+5.59), PFE: 32.43 (+1.09), NCOM: 23.33 (+0.32), UNTD: 11.07 (+0.12), HSP: 89.84 (+0.01)
Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE(R) (palbociclib), for Patients with Hormone Receptor-Positive Early Breast Cancer
Business Wire - Wed Aug 26, 6:30AM CDT
The Alliance Foundation Trials, LLC (AFT), the Austrian Breast & Colorectal Cancer Study Group (ABCSG) and Pfizer Inc. today announced the launch of the Palbociclib Collaborative Adjuvant Study, or PALLAS. This global Phase 3 clinical trial for patients with early-stage breast cancer is being conducted in conjunction with Breast International Group (BIG), German Breast Group (GBG), National Surgical Adjuvant Breast and Bowel Project (NSABP) and PrECOG, LLC (PrECOG). The PALLAS trial will evaluate whether the addition of IBRANCE(R) (palbociclib), developed by Pfizer, to standard therapy will improve disease-free survival and prevent the disease from recurring. Patients treated in this study will have cancers that are hormone receptor-positive (HR+), meaning their growth is fueled by the hormone estrogen, but are negative for human epidermal growth factor receptor 2 (HER2-), a different tumor-associated protein. About 60 to 65 percent of breast cancers in the United States fall into this category.i
PFE: 32.43 (+1.09)
Alvogen to Acquire Product Portfolio from Pfizer for the U.S. Market
Business Wire - Wed Aug 26, 5:12AM CDT
Alvogen has entered into a definitive agreement with Pfizer Inc. (NYSE: PFE), under which it will acquire a portfolio of four pharmaceutical products, in the U.S.
PFE: 32.43 (+1.09)
Best Buy and DSW are big market movers
AP - Tue Aug 25, 3:37PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
MDT: 72.24 (+2.36), EXC: 31.44 (+1.04), PFE: 32.43 (+1.09), GAS: 60.79 (-0.05), SAFM: 68.19 (+0.35), BBY: 35.25 (+2.30), BAC: 16.06 (+0.80), EPZM: 17.52 (+0.48), BA: 129.34 (+3.85), SO: 43.61 (+1.11), ECA.TO: 8.34 (+0.34), HSP: 89.84 (+0.01), CIE: 7.92 (-0.02), EXCU: 46.82 (+1.31), DSW: 28.67 (+1.32), ECA: 6.26 (+0.27), POM: 23.40 (+0.89), WB: 11.00 (+0.34), CVX: 73.09 (+3.07)
When Looking for Market Help, Rigor Is Essential
at The Street - Tue Aug 25, 11:01AM CDT
USA Today's '9 Stocks' story doesn't consider data essential to its narrative.
PLL: 126.57 (+0.30), SIAL: 139.01 (-0.05), PFE: 32.43 (+1.09), DHR: 86.67 (+3.44), SO: 43.61 (+1.11), HSP: 89.84 (+0.01)
These 4 Resilient Stocks Survived Monday's Selloff
Swarup Gupta - Zacks Investment Research - Tue Aug 25, 9:15AM CDT
Stocks which have survived the strongest selloff in recent times make for good additions to your portfolio.
SWKS: 86.15 (+5.59), NCOM: 23.33 (+0.32), PFE: 32.43 (+1.09), UNTD: 11.07 (+0.12), HSP: 89.84 (+0.01)
Company News for August 25, 2015
Zacks Equity Research - Zacks Investment Research - Tue Aug 25, 9:10AM CDT
Companies in the News are: GAS,SO,HSP,PFE,TOUR,QFOR
PFE: 32.43 (+1.09), GAS: 60.79 (-0.05), SO: 43.61 (+1.11), TOUR: 11.40 (-1.55), HSP: 89.84 (+0.01)
Pfizer's Stephen Baker Joins Innovive Inc
Business Wire - Tue Aug 25, 7:00AM CDT
Innovive Inc, the leader in disposable IVC rodent caging, today announced that Stephen Baker has joined the company as Vice President of Business Development.
PFE: 32.43 (+1.09)
Still Not Cheap? Not So Fast
at The Street - Tue Aug 25, 6:52AM CDT
This cautionary story misses big details about the stocks it's warning about.
PLL: 126.57 (+0.30), SIAL: 139.01 (-0.05), PFE: 32.43 (+1.09), DHR: 86.67 (+3.44), SO: 43.61 (+1.11), HSP: 89.84 (+0.01)
Pfizer awarded final regulatory approvals for pending acquisition of Hospira
M2 - Tue Aug 25, 4:06AM CDT
Pfizer (NYSE
FE) declared on Monday that the US Federal Trade Commission has terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to its pending acquisition of Hospira (NYSE:HSP). PFE: 32.43 (+1.09), HSP: 89.84 (+0.01)
Pfizer says Hospira purchase will close in early September
AP - Mon Aug 24, 6:39PM CDT
NEW YORK (AP) — Drugmaker Pfizer says it's received the final regulatory approvals for its $15.23 billion purchase of the injectable drug and infusion device maker Hospira, and says the deal will close in early September.
PFE: 32.43 (+1.09), HSP: 89.84 (+0.01)
After Yesterday's Decline of 4.20%, Pfizer Offers Investors Better Value
Comtex SmarTrend(R) - Mon Aug 24, 4:53PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $28.47 to a high of $33.25. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $33.54 on volume of 51.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PFE: 32.43 (+1.09)
Pfizer Set to Possibly Rebound After Yesterday's Selloff of 4.20%
Comtex SmarTrend(R) - Mon Aug 24, 4:53PM CDT
Pfizer (NYSE
FE) traded in a range yesterday that spanned from a low of $28.47 to a high of $33.25. Yesterday, the shares fell 4.2%, which took the trading range below the 3-day low of $33.54 on volume of 51.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. PFE: 32.43 (+1.09)
Flash Crash-Like Selloff Met by Buyers; Cook’s Letter to Cramer Was ‘Significant’
at The Street - Mon Aug 24, 2:10PM CDT
The CNBC ‘Fast Money’ traders break down Monday’s violent selloff and subsequent rally. Apple CEO Tim Cook’s letter to Jim Cramer gave investors some clarity on China.
SBUX: 53.96 (+2.87), HD: 115.93 (+4.96), GILD: 106.96 (+4.40), PFE: 32.43 (+1.09), VZ: 45.16 (+1.66), AAPL: 109.69 (+5.95), CELG: 119.23 (+6.53)
Best in Breed: Where to Look If You Simply Must Buy Stocks Today
at The Street - Mon Aug 24, 12:00PM CDT
Limit your purchases to high-yielding industry standouts.
JNJ: 95.11 (+4.38), JPM: 62.91 (+3.00), IBM: 146.70 (+5.74), PFE: 32.43 (+1.09), KHC: 73.91 (+3.70), WMT: 64.83 (+1.73), XOM: 72.50 (+3.79), WFC: 52.30 (+2.28), BRK.B: 132.61 (+4.87), BRK.A: 200,499.92 (+6,300.00), AAPL: 109.69 (+5.95)
Pfizer (PFE) Crosses Pivot Point Support at $33.20
Comtex SmarTrend(R) - Mon Aug 24, 11:51AM CDT
Shares of Pfizer (NYSE
FE) have bearishly opened below the pivot of $33.88 today and have reached the first support level of $33.20. Analysts will be watching for a cross of the next downside pivot targets of $32.86 and $31.84. PFE: 32.43 (+1.09)
Pfizer (PFE) Stock Lower, Receives Regulatory Approval for Hospira Purchase
at The Street - Mon Aug 24, 10:28AM CDT
Pfizer (PFE) shares are down despite the company receiving regulatory approval for its $15.23 billion purchase of smaller rival Hospira (HSP).
PFE: 32.43 (+1.09)
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015
Business Wire - Mon Aug 24, 7:15AM CDT
--Results from the AEGEAN (Assessment of an Educational and Guidance Programme for Eliquis Adherence in Nonvalvular Atrial Fibrillation) study will also be presented as a late-breaking trial
PFE: 32.43 (+1.09), BMY: 60.03 (+2.15)
Halozyme Enzyme Could Boost Power Of Cancer Drugs
at Investor's Business Daily - Mon Aug 24, 7:02AM CDT
Halozyme Therapeutics has been one of 2015's hotter biotech stocks, but it's not exactly because of developing a drug. Halozyme's (HALO) one marketed product, Hylenex, aids in the delivery of injectable drugs. Halozyme has also licensed Enhanze for...
JNJ: 95.11 (+4.38), HALO: 17.46 (+0.58), PFE: 32.43 (+1.09), AMGN: 153.98 (+8.79), ABBV: 63.14 (+2.43), BXLT: 35.45 (+0.72), CELG: 119.23 (+6.53)
Pfizer Receives Clearance from U.S. Federal Trade Commission for Hospira Acquisition
Business Wire - Mon Aug 24, 7:00AM CDT
--Brazil's Superintendency-General of the Council for Economic Defense (CADE) has published its unconditional clearance decision
PFE: 32.43 (+1.09), HSP: 89.84 (+0.01)
